AbSci Establishes New Collaboration with Sanofi

VANCOUVER, Wash., Jan. 9, 2019 /PRNewswire/ -- AbSci, a global leader in biotherapeutic discovery and manufacturing technologies, today announced a collaboration with Sanofi.  Under the terms of the agreement, AbSci will apply its breakthrough E.coli manufacturing platform, SoluPro^TM, and its novel optimization assay system, to two of Sanofi's biotherapeutic molecules. AbSci's proprietary technology platform is designed with the ability to rapidly achieve optimized, scalable, high-quality, high-titer production of any class of biotherapeutic molecule, including traditionally difficult to manufacture molecules and next-generation scaffolds. The collaboration will take place at AbSci and be funded by Sanofi.

"It is exciting to partner with a renowned company like Sanofi," said Sean McClain, CEO of AbSci. "This collaboration illustrates the need for new expression technologies that are capable of producing these next-generation antibody and protein scaffolds. We've shown SoluPro^TM can uniquely deliver on this industry need."

About AbSci

AbSci is a global leader in biomanufacturing technologies. Its patented SoluPro™ expression platform rapidly produces complex proteins, ranging from mAbs, Fabs, enzymes, hormones and peptides to the most novel classes of biotherapeutics, at high-titers and high-quality. AbSci's unique approach increases discovery throughput, accelerates development, reduces manufacturing costs, and increase plant capacity for the biopharmaceutical industry. For more information, please visit www.absci.com.

SOURCE AbSci

Related Links

http://www.absci.com